BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Mesoblast Limited Release: Key Mesenchymal Precursor Cell Patents Granted in United States and China


2/7/2013 12:03:31 PM

Melbourne, Australia; 7 February 2013: Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted three key new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of the People’s Republic of China. These patents deliver major commercial advantages and offer long term protection in these territories for the company’s products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform.

In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive rights through to March 2029 to compositions-of-matter covering its current products. This patent extends by more than seven years Mesoblast's exclusive commercial rights in the United States, the world’s largest healthcare market, to MPC compositions-of-matter beyond those rights already conferred by USPTO patents 7,122,178 and 8,158,118 whose expiry had previously been extended to November 2021.

In China, patents CN200580040212.1 and CN200580039970.1 provide Mesoblast with exclusive MPC product commercial rights and protection through to 2025. These patents provide Mesoblast with long-term composition-of-matter protection for the company's MPC products derived from an unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord, and dental pulp. These Chinese patents underpin Mesoblast's corporate strategy to target the world’s largest emerging market for regenerative medicines, and to protect its manufacturing processes and know-how.

Mesoblast Limited

Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for a broad range of major clinical diseases, including inflammatory and immunologic conditions, diabetes and its complications, orthopedic spine conditions, and cardiovascular disorders. www.mesoblast.com

For further information, please contact:

Julie Meldrum

Global Head of Corporate Communications

T: + 61 3 9639 6036

E: julie.meldrum@mesoblast.com

For media queries, please contact:

Melanie Toyne Sewell/ Gemma Howe

College Hill

T: + 44 20 7866 7860

E: mesoblast@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->